不同癌症中的 KRAS 突变亚型：KRAS 突变亚型在不同癌症中分布各异。胰腺癌、结直肠癌和胃癌中，G12D 突变最为常见；子宫癌中 G12V 突变占主导；肺癌中 G12C 突变最为频繁。例如，在胰腺癌的 KRAS 突变中，G12D 突变占 46.5%，G12V 突变占 31.6%；在结直肠癌中，G12D 突变 ...

Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

KRAS mutations, especially G12D, G12V, and G12C, are highly prevalent ... limited to a subset of patients with a single type of KRAS mutation (G12C).

QTX3544 is an oral, G12V-preferring, dual ON/OFF state ... but their impact is limited to a subset of patients with a single type of KRAS mutation (G12C). We sell different types of products ...

KRAS mutations, especially G12D, G12V, and G12C, are highly prevalent in pancreatic, colorectal, and lung cancers. First-generation KRAS inhibitors have demonstrated clinical benefit, but their impact ...

While mutation-specific KRAS inhibitors that target the KRAS OFF-state have demonstrated clinical benefit, highly prevalent KRAS mutations such as G12D and G12V exist predominantly in the ON-state ...

NEW YORK – Alterome Therapeutics said on Monday it has started treating patients with KRAS-mutant advanced solid tumors with its KRAS inhibitor ALTA3263 in a Phase I trial.